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Abstract
Objective In subjects with idiopathic Parkinson’s disease (PD) the functional state of the locus coeruleus and the subtle 
derangements in the finely tuned dopamine–noradrenaline interplay are largely unknown. The PET ligand (S,S)-[11C]-O-meth-
ylreboxetine (C-11 MRB) has been described to reliably bind noradrenaline transporters but long scanning protocols might 
hamper its use, especially in patients with PD. We aimed to assess the feasibility of reducing C-11 MRB scans to 30 min.
Methods Ten patients with idiopathic PD underwent dynamic C-11 MRB PET (120 min duration) and brain magnetic reso-
nance imaging. Model-based (i.e., simplified and multilinear reference tissue model 2) non-displaceable binding potentials 
(BP) of selected brain regions were analyzed for a 90 min scan protocol and compared with BP derived from static 30-min 
data with different starting times (30, 40, 50 and 60 min) after C-11 MRB injection. Intraclass correlation coefficient and 
linear regression analysis were used to explore the association between BP of different scan durations. Spearman’s ρ served 
to describe the correlation of BP with demographic and clinical parameters.
Results With respect to kinetic models,  BP50–80 and  BP60–90 showed the best correlation in several brain areas (R2 range 
0.95–98; p < 0.001). The thalamus showed the highest BP on average. No correlation between BP, clinical and demographic 
characteristics was observed.
Conclusions An acquisition time of 30 min, starting 50 or 60 min after C-11 MRB injection, allows a reliable estimation 
of noradrenaline transporter binding values in Parkinsonian people. A short acquisition time can significantly reduce the 
discomfort of Parkinsonian patients and facilitate PET studies, especially in the medication-off-state.
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Introduction
Parkinson’s disease (PD) has been historically identified 
as a nigrostriatal dopamine deficiency syndrome. The dra-
matic response of most motor and some non-motor symp-
toms to dopaminergic therapies, coupled with milestone 
achievements in the understanding of the dysfunction of 
dopamine homeostasis, furthered this belief [1–3]. How-
ever, dopamine neurotransmission may not be the first nor 
the major neurotransmitter casualty in the pathophysiology 
of PD [4]. In this respect, there is increasing awareness of 
variable derangements of non-dopaminergic modulatory 
systems (e.g., noradrenaline, acetylcholine, and glutamate). 
However, the general belief is still that the symptoms of PD 
parallel a neurodegenerative process [4, 5], although certain 
symptoms relate more to adaptive changes and compensa-
tory adjustments than to slowly progressive dopaminergic 
failure. As an example, levodopa-related dyskinesia might 
be due to aberrant release of dopamine from serotonin neu-
rons [6], or preserved striatal cholinergic functions [7]. We 
also advanced the hypothesis that parkinsonian tremor could 
result from increased noradrenergic activity arising from the 
locus coeruleus (LC) [8], which could also be responsible for 
the benign progression of PD in patients with tremor, owing 
to a putative neuroprotective and compensatory activity of 
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noradrenaline on its target neurons (including the substantia 
nigra and the striatum) [9, 10]. This hypothesis has recently 
been supported by a preliminary study in PD patients with 
positron emission tomography (PET) using (S,S)-11C-2-(α-
(2-methoxyphenoxy)benzyl)morpholine, also called (S,S)-
[11C]-O-methylreboxetine (C-11 MRB), a selective ligand 
for noradrenaline reuptake transporters (NET), which are 
localized on noradrenergic synaptic terminals [11]. Informa-
tion on the noradrenergic terminal density in people with 
PD is largely missing and our knowledge derives from his-
topathological examinations, mostly performed in advanced 
stages of the disease, when compensatory mechanisms are 
eventually exhausted. Molecular imaging studies in vivo are 
needed, but have long been hampered by the lack of suit-
able radioligands. One imaging study used the tracer C-11 
RTI-32 to specifically address the noradrenergic activity 
of the central nervous system in PD patients. The authors 
showed reduced catecholamine transporter density in the 
LC and in several regions of the limbic system in depressed 
PD patients [12]. Recently, Nahimi et al. [11] evaluated the 
suitability of the ligand C-11 MRB for use in PD patients 
and observed decreased binding in the thalamus and nucleus 
ruber, particularly in akinetic-rigid dominant PD patients. 
Furthermore, a widespread reduced binding of C-11 MRB 
was found in PD patients with REM sleep behavior disor-
ders, which correlated with the amount of REM sleep with-
out atonia [13]. C-11 MRB was developed by Ding et al. [14, 
15] for the exploration of NET availability in patients with 
psychiatric disorders [16–18]. The main practical limitation 
of C-11 MRB is the long scan duration; the published scan-
ning protocols comprise dynamic PET scans over at least 
90 min [11, 17, 18]. Long protocols, however, cause major 
discomfort for patients with PD, especially when pausing 
dopaminergic medication. Arterial input function measure-
ments, to quantify the volume of distribution, could be less 
of a problem by replacing with the simplified reference tis-
sue model (SRTM) 2 [19] or Ichise’s multilinear reference 
tissue model (MRTM) 2 [20, 21]. These models, as well 
as the use of the caudate or the occipital cortex as possible 
reference regions, have recently been validated in people 
with PD [11]. The aim of this study was to investigate the 
validity of shorter scanning protocols for C-11 MRB PET in 
PD patients. We compared non-displaceable binding poten-
tials (BP) of cortical and subcortical brain regions estimated 
using a 30-min scan duration that started between 30 and 
60 min post-injection, with the model-derived binding val-
ues obtained by SRTM2 and MRTM2. Furthermore, we 




We consecutively recruited eight men and two women 
with a diagnosis of PD according to the UK Brain Bank 
Clinical Diagnostic criteria for PD. Disease severity and 
stage was assessed with the Unified Parkinson’s Disease 
Rating Scale (UPDRS) and the Hoehn and Yahr (H/Y) 
scale. Patients were clinically investigated in the morning 
after overnight withdrawal (> 12 h) of all dopaminergic 
drugs (meds-off) and at 1 h (meds-on) after oral intake 
of 200/50 mg fast-release soluble levodopa/benserazide. 
Clinical and demographic data are listed in Table  1. 
Patients with significant comorbidity, previous history of 
other neurological conditions (e.g., stroke and epilepsy), 
dementia, depression or sleep disorders (e.g., REM sleep 
behavior disorder) were not enrolled. None of the patients 
were taking antipsychotics, antidepressants, or other 
Table 1  Patient characteristics
DD disease duration, H/Y Hoehn and Yahr stage, UPDRS Unified Parkinson’s Disease Rating Scale, LEDD 
levodopa-equivalent daily dose







1 M 59 16 2 30 13 405
2 M 59 3 1 14 3 408
3 M 73 2 3 28 10 450
4 M 65 6 3 36 19 720
5 F 54 2 1 11 6 260
6 M 53 4 1 22 15 557
7 F 61 3 1 25 18 450
8 M 53 3 2 20 16 720
9 M 64 2 1 11 8 780
10 M 64 3 1 15 9 310
Mean ± SD 60.5 ± 6.3 4.4 ± 4.2 1.6 ± 0.8 21 ± 8.5 8.3 ± 7.1 50 ± 181
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drugs possibly affecting the noradrenergic system. C-11 
MRB was administered on a compassionate use basis in 
compliance with §37 of the Declaration of Helsinki and 
The German Medicinal Products Act, AMG §13.2b. MRI 
was performed as part of the clinical work-up. The study 
was approved by the local institutional review board (IRB 
approval: 2017040601). All patients gave written informed 
consent to the diagnostic procedures.
Preparation of C‑11 MRB
(2S,3S)-Desethylreboxetine used as precursor for radiola-
beling and the MRB reference were purchased from ABX 
(Radeberg, Germany). All solvents and reagents were 
provided in Ph. Eur. quality from Merck KG (Darmstadt, 
Germany) or AppliChem GmbH (Darmstadt, Germany).
C-11 MRB was synthesized on a Tracerlab-Fx-C-Pro 
synthesis unit (GE Medical Systems, Uppsala, Sweden) 
following the method published previously by Ding et al., 
with minor modifications [18, 22]. The radiochemical 
yield was typically between 4.5 and 5.5 GBq per batch 
with a specific activity, as determined by analytical HPLC 
and MRB reference, of 40–60 GBq/µmol (EOS) in a total 
synthesis time of 45 min.
PET scans
PET scans were obtained with a combined PET/CT scan-
ner (Biograph mCT 64; Siemens Healthineers, Knoxville, 
TN, USA). Prior to the acquisition, an intravenous catheter 
was placed in the antecubital vein of the left or right arm. 
The patients were positioned comfortably in the PET scan-
ner and instructed to remain still for the total duration of 
the scan. The patient’s head was fixed in a head holder to 
avoid motion artefacts. After the acquisition of a low-dose 
CT for attenuation correction (CARE Dose 4D, 80 mAs, 
120 kV; matrix: 512 × 512; 2-mm slice thickness; incre-
ment: 30 mm/s; rotation time: 0.5 s; pitch index: 0.8), C-11 
MRB was administered intravenously as a slow manual 
bolus injection of 635 ± 29 MBq. Simultaneously with 
the injection, a dynamic PET acquisition with 120 min 
duration was initiated using the 3D list mode. After the 
acquisition, the data were binned in 33 frames of pro-
gressively longer durations (6 × 30 s, 3 × 60 s, 2 × 120 s, 
22 × 300 s), and PET images were reconstructed iteratively 
(HD-PET, 24 subsets, 3 iterations; Gaussian filtering: 
5.0 mm; matrix: 400 × 400; axial resolution: 2.0 mm; in-
plane resolution: 2.04 × 2.04 mm2). Acquisition and data 
reconstruction were performed using dedicated manufac-
turer software (syngo MI.PET/CT; Siemens Healthineers, 
Erlangen, Germany).
MR imaging
Magnetic resonance imaging (MRI) was performed on a 3T 
whole-body scanner (MAGNETOM Trio; Siemens Health-
ineers, Erlangen, Germany) equipped with a 12-channel, 
phased-array head coil for signal reception. In all subjects, 
a standard cranial MRI protocol was applied, including 
an isotropic high-resolution structural T1-weighted MP-
RAGE-Sequence (Turbo-FLASH 1.0 × 1.0 × 1.0 mm3, TR 
2530 ms, TE 3.37 ms, FA 9°, TI 1200 ms) for anatomical 
co-registration with the PET images.
Image analysis
Data preprocessing
All image data were processed and analyzed using PMOD 
image analysis software version 3.7 (PMOD Technolo-
gies Ltd, Zurich, Switzerland). Dynamic PET data were 
motion-corrected to a late time point image [40–45 min 
post-injection (p.i.)] of the scan. An average PET image 
of 20–60 min p.i. of the motion-corrected time series was 
calculated for each subject. Based on this, the dynamic 
PET scan was registered and matched to the individuals’ 
MP-RAGE image volume. Furthermore, four static PET 
images of 30 min scan time were created for each patient 
by averaging over six consecutive of these preprocessed 
frames starting at 30, 40, 50 and 60 min.
VOI definition
Three probability maps were obtained, based on the indi-
viduals’ MP-RAGE sequence, by applying the segmenta-
tion method [23]. Normalization of the MR images was 
performed via probability maps transformation into the 
standard anatomical space of the Montreal Neurological 
Institute (MNI) [24]. Based on the N30R83 maximum 
probability atlas by Hammers and colleagues [25], 17 tar-
get volumes of interest (VOIs) were defined: amygdala 
(left/right; l/r), brainstem, caudate nucleus (l/r), cerebel-
lum (l/r), frontal lobe (l/r), hippocampus (l/r), parietal 
lobe (l/r), putamen (l/r) and thalamus (l/r). Two additional 
atlas-based auxiliary VOIs were created, one containing 
the regions of the occipital lobe, and a second by merging 
the left and right thalamus. The transformation between 
the patient brain and the MNI space was then used to 
inversely transform the VOIs to the individuals’ MRI and 
the co-registered PET space. Last, a VOI containing the 
LC was outlined using previously published atlas coordi-
nates [26].
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Kinetic modeling
VOI-specific time activity curves (TAC) from 0 to 90 min 
p.i. were generated from the dynamic PET data for each 
patient. To determine the efflux rate constant ( k′
2
 ), one-
parameter MRTM was applied for each of these TACs using 
the fused thalamus VOI as the transporter-rich region and 
the occipital lobe as the reference region. Then, the mean k′
2
 
of all ten patients was calculated and transferred to the two-
parameter MRTM2 and SRTM2 (20) to determine binding 
values  (BPMRTM2 and  BPSRTM2) of the eighteen target VOIs 
for each patient. Additionally, BP of the four static brain 
PETs was calculated for each of the above regions using 
average regional uptake values [BP = (mean activity con-
centration VOI − mean activity concentration occipital cor-
tex)/(mean activity concentration occipital cortex)]. 30-min 
time frames starting at four different times p.i. were used 
 (BP30–60,  BP40–70,  BP50–80,  BP60–90).
Statistical analysis
Clinical variables and BP estimates were tested for normal-
ity using the Shapiro–Wilk test. We calculated (region-wise) 
the Spearman’s rank correlation coefficient (Spearman’s ρ) 
and the intraclass correlation coefficient (ICC) between 
 BP30–60,  BP40–70,  BP50–80 or  BP60–90 and the model-based 
binding values  (BPMRTM2 and  BPSRTM2). A linear regression 
analysis was used to describe the correlation between bind-
ing values provided by the four static 30-min brain PETs and 
the two model-derived  BPMRTM2 and  BPSRTM2 (all regions). 
The association between the binding value of the thalamus 
with age and clinical variables [i.e., disease duration, H/Y 
stage, UPDRS-III score, and levodopa-equivalent daily 
dose (LEDD)] was evaluated with a multivariate analysis 
of variance and Spearman’s ρ. Of note, we assumed no rel-
evant influence of laterality on time-dependent BP and we 
pooled left and right hemisphere for all paired brain regions. 
Significance was set at p < 0.05 and corrected for multiple 
comparisons.
Results
Region-wise correlational analyses are listed in Tables 2 
and 3. The linear regression analysis is shown in Figs. 1 
and 2. With respect to the model-derived binding val-
ues,  BP60–90  (BP60–90 = 0.97 × BPSRTM2 − 0.01, R2 = 0.97, 
p < 0.001;  BP60–90 = 0.96 × BPMRTM2 − 0.01, R2 = 0.96, 
p < 0.00) and  BP50–80  (BP50–80 = 0.93 × BPSRTM2 − 0.01, 
R2 = 0.96, p < 0.001;  BP50–80 = 0.90 × BPMRTM2 − 0.02, 
R2 = 0.95, p < 0.001) showed a very high correlation. Less 
significant prediction values were observed for  BP40–70 
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 BP40–70 = 0.83 × BPMRTM2 − 0.03, R2 = 0.91, p < 0.001) 
and  BP30–60  (BP30–60 = 0.81 × BPSRTM2 − 0.03, R2 = 0.90, 
p < 0.001;  BP30–60 = 0.77 × BPMRTM2 − 0.04, R2 = 0.84, 
p < 0.001). The highest average BP value was found in the 
thalamus, followed by the putamen and the LC. The average 
thalamic NET binding potential ranged between 0.22 and 
0.27 for  BPMRTM2,  BPSRTM2,  BP50–80 and  BP60–90, whereas 
it was lower for  BP30–60 and  BP40–70 (0.17 and 0.19). No sig-
nificant correlations between BP, demographic, and clinical 
parameters were found.
Discussion
This study suggests that an acquisition time of 30 min for 
C-11 MRB PET can offer a reliable estimation of cerebral 
NET density. This information is of relevance to reduce the 
scan duration and therefore the discomfort of Parkinsonian 
patients.
Acquisitions starting at 50 and 60 min showed higher 
correlation values regarding  BPSRTM2 and  BPMRTM2 than the 
scans starting at 30 and 40 min p.i. (Figs. 1, 2). This finding 
suggests that for C-11 MRB, many cortical and subcortical 
regions reach a stable equilibrium at later time points of the 
scan. An early start combined with a short acquisition dura-
tion might partially capture the tracer distribution before 
the equilibrium has been reached. Additionally, it might not 
even cover the phase of stable equilibrium occurring at later 
time points. Accordingly, scans of 30 min duration starting 
at a later time point (50 or 60 min) showed better ICC val-
ues for all tested brain regions (Tables 2, 3). These results 
are in line with previous PET studies on the noradrenergic 
system showing stable TACs for the thalamus, the basal gan-
glia, the cerebellum, and cortical regions between 50 and 
90 min p.i. using C-11 MRB [27], C-11 MENET [28], or 
F-18 FMeNER-D2 [29].
Previous studies in non-human primates and humans 
tested the caudate nucleus, the putamen, and the occipital 
cortex as potential reference regions for C-11 MRB [30, 31]. 
In PD patients, only the caudate and the occipital cortex 
have been validated for this ligand, with the latter showing 
slightly lower BP [11]. Besides methodological issues [21], 
we chose the occipital cortex as a reference because of the 
important role of the caudate nucleus in the pathophysiology 
of PD. Motor PD symptoms appear when the loss of puta-
men dopamine level reaches 70–80%, which corresponds to 
a 50–60% decrease in dopamine neurons [32, 33]. The cau-
date nucleus is instead relatively spared at early stages of PD 
[34] and represents a possible site of still-active compensa-
tory and neuroprotective mechanisms upon motor symptoms 
onset [7], also involving the noradrenergic system arising 








































































































































































































































































































































































































































































































































































































































































































































































































 is the clearance rate constant from 
the reference region to plasma, and needs to be defined 
a priori for the reference methods SRTM2 and MRTM2 
[20]. This parameter can be estimated for each subject by 
applying the three-parameter model MRTM to the individ-
ual TAC of a high-binding region and a reference region 
(in our case, the thalamus and the occipital brain area, 
respectively). In the cohort of this study, an average k′
2
 of 
0.0322 ± 0.0105 min− 1 was determined. It is in the range 
of previously measured values of k′
2
 based on one-tissue 
compartment modeling with arterial input measurements 
in PD patients and healthy controls [11].
Finally, with regard to the actual NET measurements, the 
 BP50–80 and  BP60–90 shown in this study (Tables 2, 3) are in 
line with previous reports [11, 13, 18, 28, 29]. Multivari-
ate analysis of variance showed no significant correlation 
between any BP of noradrenaline transporters and demo-
graphic or clinical measures (i.e., disease duration, disease 
severity and LEDD) in all brain regions investigated. These 
findings are in line with studies showing a negative correla-
tion between age and BP of the thalamus and LC only in 
young healthy subjects (mean age: 35 years) [18], but not 
in the elderly (mean age: 66 years) and PD patients [11]. 
The small sample size of our study population, as well as 
Fig. 1  Scatter plots and linear regression analysis of statically derived 
binding potentials (BP) and binding values estimated with the Simpli-
fied Reference Tissue Model 2 (SRTM2). The upper row shows the 
BP of 30-min scan durations with acquisition start at 30 min (a) and 
40 min (b), the lower row shows BP starting at 50 min (c) and 60 min 
(d). All comparisons were plotted on BP estimated with the SRTM2. 
Regression lines are depicted in grey
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the results of previous studies, however, prevent any firm 
conclusion on demographic and clinical correlations of C-11 
MRB binding values. In our case, while disease severity and 
LEDD were reasonably well represented in our study cohort 
(Table 1), all but two subjects had disease duration below 
5 years and only two females were included in this study. 
Furthermore, no optical tracking system for motion cor-
rection was available, which can considerably improve the 
analysis of small brain areas such as the LC. Nevertheless, 
also in agreement with Nahimi et al. [11], it is of relevance 
to note that C-11 MRB binding was not influenced by the 
dosage of dopaminergic drugs (i.e., LEDD). This result also 
parallels previous findings on dopamine reuptake transporter 
binding values measured with I-123 FP-CIT and SPECT 
[36]. Further studies are warranted to deepen our under-
standing of the noradrenergic system in people with PD, 
with emphasis on clinical phenotypes (e.g., tremor-dominant 
PD) [37], compensatory and protective mechanisms [8–10].
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zburg and by the “Fondazione Grigioni per il Morbo di Parkinson”.
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Fig. 2  Scatter plots and linear regression analysis of statically derived 
binding potentials (BP) and binding values estimated with Ichise’s 
Multilinear Reference Tissue Model 2 (MRTM2). The upper row 
shows the BP of 30-min scan durations with acquisition start at 
30 min (a) and 40 min (b), the lower row shows BP starting at 50 min 
(c) and 60  min (d). All comparisons were plotted on BP estimated 
with the MRTM2. Regression lines are depicted in grey
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